drugset / Trial / NCT01565096
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Phase 4
Unknown
44 enrolled
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development · collabNovartis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to glimepiride on beta cell function and the cardiovascular risk profile in patients previously treated with Metformin monotherapy.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glimepiride | Small molecule | — | — |
| Subject | Vildagliptin | Other / unclassified | 50 mg | — |
| Comparator | Metformin | Small molecule | 1000 mg | — |